Related Experiment Videos
Role of rectal formulations: enemas
M Campieri1, P Gionchetti, A Belluzzi
1Institute of Clinical Medicine and Gastroenterology, University of Bologna, Italy.
Scandinavian Journal of Gastroenterology. Supplement
|January 1, 1990
Summary
Mesalazine enemas are effective and safe for treating ulcerative colitis, especially for patients intolerant to sulfasalazine or unresponsive to other therapies. This treatment is suitable for mild to moderate cases and maintenance therapy.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Current treatments for UC have limitations, necessitating alternative therapeutic options.
Purpose of the Study:
- To review the clinical experience and efficacy of mesalazine enemas in treating ulcerative colitis.
- To evaluate the safety and tolerability of mesalazine enemas.
Main Methods:
- Review of clinical data on mesalazine enema use in ulcerative colitis patients.
- Analysis of plasma mesalazine levels and urinary excretion after rectal administration.
- Assessment of efficacy in mild to moderate UC and for maintenance therapy.
Main Results:
- Rectal administration of mesalazine enemas results in low plasma levels and minimal urinary recovery.
- Mesalazine enemas (2g and 4g) demonstrate effectiveness, safety, and good tolerability in mild to moderate UC.
- Successful treatment outcomes were observed in patients intolerant to sulfasalazine or unresponsive to other therapies.
- Mesalazine enemas are beneficial for extensive disease and maintenance therapy, complementing suppositories for distal disease.
Conclusions:
- Mesalazine enemas are a valuable therapeutic option for ulcerative colitis, particularly for specific patient groups and disease extents.
- The safety and efficacy profile supports the use of mesalazine enemas in managing ulcerative colitis.